DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low risk0–0
- Intermediate-1 risk1–2
- Intermediate-2 risk3–4
- High risk5–8
The DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include scoring system. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates survival in patients with primary myelofibrosis using clinical and laboratory parameters
Clinical Indication
The DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis is indicated for bedside clinical practice to support Estimates survival in patients with primary myelofibrosis using clinical and laboratory parameters. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.
DIPSS Score: Age >65 (1 point) + WBC >25,000/μL (1 point) + Hemoglobin <10 g/dL (2 points) + Peripheral blast ≥1% (1 point) + Constitutional symptoms (1 point). DIPSS Plus adds: Unfavorable karyotype (1 point) + Platelets <100,000/μL (1 point) + Transfusion dependency (1 point).
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| scoring_system | string | Yes | Choose DIPSS or DIPSS Plus scoring system |
| age_over_65 | string | Yes | Age greater than 65 years |
| wbc_over_25 | string | Yes | White blood cell count >25,000/μL (25 × 10⁹/L) |
| hemoglobin_under_10 | string | Yes | Hemoglobin <10 g/dL (100 g/L) |
| peripheral_blast_1_or_more | string | Yes | Peripheral blood blast ≥1% |
| constitutional_symptoms | string | Yes | Constitutional symptoms (fever, night sweats, weight loss >10% in 6 months) |
| unfavorable_karyotype | string | No | Unfavorable karyotype (complex karyotype or sole/two abnormalities including +8, -7/7q-, i(17q), -5/5q-, 12p-, inv(3), or 11q23 rearrangement) - Required for DIPSS Plus |
| platelets_under_100 | string | No | Platelet count <100,000/μL (100 × 10⁹/L) - Required for DIPSS Plus |
| transfusion_dependent | string | No | Red cell transfusion dependency - Required for DIPSS Plus |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Low risk | Low risk category |
| 1–2 | Intermediate-1 risk | Intermediate-1 risk category |
| 3–4 | Intermediate-2 risk | Intermediate-2 risk category |
| 5–8 | High risk | High risk category |
Evidence-Based References (EBM)
- Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-8.
- Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-7.